Dermata Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.46M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Press releases
Announcements Dermata Therapeutics filed with the SEC
Dermata Therapeutics Announces $3.4 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces up to $12.4 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata’s XYNGARI™ Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BREAKING: Dermata’s XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Announces $2.55 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
DERMATA AND REVANCE ENTER CLINICAL TRIAL COLLABORATION AGREEMENT FOR THE TOPICAL APPLICATION OF XYNGARI™ WITH DAXXIFY
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Announces $3.5 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 9, 2023
Results of operations · Auditor change · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Dermata Therapeutics Provides Corporate Update and Reports First Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K